Print Page  |  Close Window

2017 News Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/11/17LabCorp Supports American Clinical Laboratory Association Lawsuit on PAMA Final Rule
Final Rule Establishes Medicare Payment Rates for Clinical Laboratory Tests That Will Harm Beneficiaries and Restrict Access to Necessary Lab Services BURLINGTON, N.C.--(BUSINESS WIRE)--Dec. 11, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, today issued the following statement regarding the lawsuit filed by the American Clinical Laboratory Association (ACLA) against the Acting Secretary of the U.S. Department of Health and... 
Printer Friendly Version
11/15/17LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb’s OPDIVO®
LabCorp Performed Testing for Studies Supporting Approval of Two New Complementary Diagnostic Indications in Connection with the Treatment of Bladder Cancer and Cancer of the Head and Neck BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 15, 2017-- LabCorp (NYSE: LH) a leading global life sciences company, today announced the U.S. availability of the PD-L1 IHC 28-8 pharmDx assay as a complementary diagnostic for two newly approved indications in connec... 
Printer Friendly Version
11/13/17LabCorp Receives 2017 Partnership Award from Be The Match®
Award Recognizes 25 Years of Innovation and Support to Help Cure Blood Cancers BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 13, 2017-- LabCorp, (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, proudly announces that it received the 2017 Partnership Award from Be The Match® on November 11 at the nonprofit’s 30th Annual Council Meeting in Minneapolis. LabCorp is a leader in providing special... 
Printer Friendly Version
11/13/17LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 16th Annual Scorecard on LGBTQ Workplace Equality
Receives Designation as a Best Place to Work for LGBTQ Equality BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 13, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, announced that it received a perfect score of 100 percent on the 2018 Corporate Equality Index (CEI), a national benchmarking survey and report on corporate policies and practices related to lesbian, gay, bisexual, transgender and queer (LGBTQ) workplace equality, administered b... 
Printer Friendly Version
11/01/17LabCorp is Scheduled to Present at the 26th Annual Credit Suisse Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 1, 2017-- LabCorp® (NYSE: LH) today announced it will participate at the 26th Annual Credit Suisse Healthcare Conference. LabCorp’s presentation is planned for Tuesday, November 7, 2017 at 10:55 am (MT). A live audio webcast will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&P 500 company, is a leading globa... 
Printer Friendly Version
11/01/17LabCorp and Capital Health Enter Comprehensive Laboratory Partnership
Collaboration Will Enhance and Streamline Laboratory Services for Patients and Physicians in Central New Jersey and Lower Bucks County, Pennsylvania BURLINGTON, N.C. & TRENTON, N.J.--(BUSINESS WIRE)--Nov. 1, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, and Capital Health, the Central New Jersey/Lower Bucks County, Pennsylvania region’s leader in providing progressive, quality patient care, announced today that they h... 
Printer Friendly Version
10/25/17LabCorp Announces Record Third Quarter Results and Increases 2017 Guidance
Q3 Net revenue of $2.6 billion, up 10% over last year Q3 Diluted EPS of $1.74, up 2% from last year; Q3 Adjusted EPS of $2.46, up 9% over last year 2017 Adjusted EPS guidance increased to $9.40 to $9.60, up 6% to 9% over 2016 2017 Free Cash Flow guidance increased to $970 million to $1,010 million, up 8% to 13% over 2016 Closed $1.2 billion acquisition of Chiltern, a lea... 
Printer Friendly Version
10/16/17Covance Recognized with Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award
BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 16, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development business (Covance) has been awarded the 2017 Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award. The award recognizes Covance’s relentless focus on delivering value to customers by offering drug development solutions that meet the unique opportunities and needs of the Asia-Paci... 
Printer Friendly Version
10/02/17Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 2, 2017-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee ... 
Printer Friendly Version
09/25/17LabCorp Objects to Proposed PAMA 2018 Medicare Payment Rates for Clinical Laboratory Tests; Calls for Delay in Implementation to Avoid Significant Harm to Medicare Beneficiaries
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 25, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, today issued the following response to the Sept. 22 publication by the Centers for Medicare and Medicaid Services (CMS) of proposed 2018 Medicare reimbursement rates for clinical laboratory tests under the Clinical Lab Fee Schedule (CLFS) pursuant to the Protecting Access to Medicare Act (PAMA). “The new PAMA rates published by CM... 
Printer Friendly Version
09/14/17LabCorp Presents Nine Studies, Including Novel Research on Improving Genetic Counseling Quality, at the National Society of Genetic Counselors Annual Conference
LabCorp’s Integrated Genetics Specialty Laboratory Leverages Decades of Experience in Genetics Research and Practice to Improve Health and Improve Lives BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 14, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, announced today that Integrated Genetics, a member of the LabCorp Specialty Testing Group, is presenting the results of nine studies relating to prenatal testing, including non-invasi... 
Printer Friendly Version
09/11/17LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 11, 2017-- LabCorp® (NYSE: LH) announced today that for the period of September 11, 2017 to March 9, 2018, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended September 8, 2017, in addition to t... 
Printer Friendly Version
09/07/17LabCorp Named Among “The World’s Most Innovative Companies” in Forbes’ 2017 Ranking
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 7, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, has been named to Forbes’ 2017 ranking of “The World’s Most Innovative Companies.” “Innovation in guiding patient care is what we do at LabCorp, so being recognized as one of the world’s most innovative companies by Forbes is a tremendous honor to our more than 57,000 dedicated colleagues,” said David P. King, chairman and CEO of LabCorp... 
Printer Friendly Version
09/05/17LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 5, 2017-- LabCorp® (NYSE:LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, September 12, 2017, at 8:35 am (ET). A live audio webcast will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE:LH), an S&P 500 company, is a leading global li... 
Printer Friendly Version
09/01/17LabCorp Completes Acquisition of Chiltern
Strengthens LabCorp’s Position as a Global Life Sciences Company with Leading Diagnostics and Drug Development Businesses BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 1, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, has completed its previously announced acquisition of Chiltern, which will become part of the company’s Covance Drug Development business. The acquisition creates a market-leading CRO, with more than 20,000 employe... 
Printer Friendly Version
08/24/17LabCorp’s Acquisition of Chiltern Clears Antitrust Review
BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 24, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that the Federal Trade Commission had granted its request for early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to LabCorp’s acquisition of Chiltern International Group Limited (Chiltern). As previously announced, LabCorp entered into a definitive agree... 
Printer Friendly Version
08/24/17LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer
Caveney is an Influential Thought Leader in Healthcare Financing, Regulatory Initiatives and Value-Based Care Models BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 24, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that Dr. Brian Caveney, a nationally recognized health-policy expert who currently serves as chief medical officer of Blue Cross and Blue Shield of North Carolina (Blue Cross NC), will fill a newly created ... 
Printer Friendly Version
08/15/17LabCorp Prices $600,000,000 in 3.250% Senior Notes Due 2024 and $600,000,000 in 3.600% Senior Notes Due 2027
BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 15, 2017-- LabCorp® (NYSE: LH) announced today that it has priced its offering of $1.2 billion in senior notes. The offering consists of two tranches: $600,000,000 aggregate principal amount of 3.250% Senior Notes due 2024 (the “2024 Notes”) and $600,000,000 aggregate principal amount of 3.600% Senior Notes due 2027 (the “2027 Notes”), (together with the 2024 Notes, the “Notes”). The Notes will bear interest from ... 
Printer Friendly Version
08/15/17LabCorp Announces Proposed Sale of Senior Notes
BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 15, 2017-- LabCorp® (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches (the “Notes”). The Notes will be senior unsecured obligations and will rank equally with LabCorp’s existing and future senior unsecured debt. LabCorp intends to use the net proceeds of the Notes offering for general corporate purpos... 
Printer Friendly Version
07/31/17LabCorp to Acquire Chiltern for Approximately $1.2 Billion in Cash, Advancing Its Leadership in Drug Development
... 
Printer Friendly Version
07/26/17LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance
Q2 Net revenue of $2.5 billion, up 5% over last year Q2 Diluted EPS of $1.82, down 7% from last year; Q2 Adjusted EPS of $2.47, up 5% over last year 2017 Adjusted EPS guidance increased to $9.30 to $9.65, up 5% to 9% over 2016 BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 26, 2017-- LabCorp® (or the “Company”) (NYSE: LH) today announced results for the second quarter ended June 30, 2017, and increased ... 
Printer Friendly Version
07/19/17LabCorp Introduces New ADAMTS13 Test for Rare Life-Threatening Blood Clot Disorder
LabCorp’s Proprietary Assay Offers Faster, More Accurate Diagnosis to Help Patients Receive Most-Appropriate Therapy BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 19, 2017-- LabCorp® (NYSE: LH) has begun offering its new, proprietary ADAMTS13 test to distinguish diseases characterized by life-threatening, acute thrombotic microangiopathy (TMA). TMA is a relatively rare but serious syndrome in which small blood vessels develop blood clots, which result ... 
Printer Friendly Version
07/18/17LabCorp’s William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center
BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 18, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that the National Evaluation System for health Technology Coordinating Center (NESTcc) has appointed William (Bill) Hanlon, Ph.D., chief development officer and head of Global Regulatory Affairs for its Covance Drug Development business, to serve on its Governing Committee. The Medical Device Innovation Consortium (MDIC), a publ... 
Printer Friendly Version
07/11/17LabCorp and Novant Health Extend Laboratory Services Agreement
Extension Demonstrates Value of LabCorp’s Health System Collaborations BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 11, 2017-- LabCorp® (NYSE: LH) and Novant Health have agreed to a multi-year extension of their Technical Services Agreement, which was first implemented in 2012. Under the agreement, LabCorp Diagnostics provides Novant Health with laboratory management services for all Novant Health acute care facilities. In addition to the T... 
Printer Friendly Version
07/03/17Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 3, 2017-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee ... 
Printer Friendly Version
06/28/17Walgreens and LabCorp Collaborate to Bring Patient Service Centers for Laboratory Testing to Select Walgreens Stores
"LabCorp at Walgreens" Sites Will Provide Specimen Collection Services for LabCorp Testing Seven Service Centers Planned to Open at Walgreens Stores in 2017 DEERFIELD, Ill. & BURLINGTON, N.C.--( BUSINESS WIRE )--Walgreens and LabCorp® (NYSE: LH) today announced a collaboration through which LabCorp will develop and operate patient service centers within select Walgreens stores. The centers, which will be co-branded "LabCorp at Walgreens," will offer LabCorp patie... 
Printer Friendly Version
06/14/17Covance Opens State-of-the-Art Laboratory for Companion Diagnostics
Dedicated Facility Furthers the Unmatched Value of the Combined Expertise of Covance Drug Development and LabCorp Diagnostics to Advance Precision Medicine BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 14, 2017-- LabCorp® (NYSE:LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business will extend its capabilities in precision medicine by opening a dedicated, state-of-the-art companion diagnosti... 
Printer Friendly Version
05/23/17LabCorp Exclusively Launches Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth
The PreTRM Test is the Only Validated Test That Provides Early and Individualized Evaluation of Preterm Birth Risk BURLINGTON, N.C.--(BUSINESS WIRE)--May 23, 2017-- LabCorp® (NYSE: LH) today announced the nationwide availability of the PreTRM® test. Developed by Sera Prognostics, Inc., the PreTRM test is the first of its kind validated blood test that provides an early and individualized prediction of preterm birth risk for pregnant women. Lab... 
Printer Friendly Version
05/09/17LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--May 9, 2017-- LabCorp® (NYSE: LH) today announced it will participate at the Bank of America Merrill Lynch 2017 Health Care Conference. LabCorp’s presentation is scheduled for Tuesday, May 16, 2017, at 10:40 a.m. PT. A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&am... 
Printer Friendly Version
05/04/17LabCorp Completes Acquisition of Pathology Associates Medical Laboratories
Transaction Establishes Relationships with Community-Based Health Systems Across Multiple StatesBURLINGTON, N.C. & RENTON, Wash. & ENGLEWOOD, Colo.--(BUSINESS WIRE)--LabCorp® (NYSE:LH) has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services (Providence) and Catholic Health Initiatives (CHI). PAML, based in Spokane, Washington, is one of the nation’s premier medical reference laboratories and a healthcare soluti... 
Printer Friendly Version
05/04/17LabCorp to Webcast Its Annual Meeting of Shareholders
BURLINGTON, N.C.--(BUSINESS WIRE)--May 4, 2017-- LabCorp® (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 11, 2017 at 9:00 a.m. Eastern Daylight Time via the Company website at www.labcorp.com. An archived replay of the audio webcast will be available for one year. About LabCorp LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply ... 
Printer Friendly Version
05/03/17LabCorp Enhances VistaSeq Hereditary Cancer Test Portfolio with Addition of New Panels and New Genes That Can Be Assessed
Expanded Test Offering Provides Targeted Insight into Risk for Hereditary Cancer Syndromes BURLINGTON, N.C.--(BUSINESS WIRE)--May 3, 2017-- LabCorp® (NYSE: LH) today announced a significant enhancement to its proprietary VistaSeqSM Hereditary Cancer portfolio, with ten new test panels focusing on the risk of specific hereditary cancer syndromes. The number of cancer genes that can be assessed has also increased to 59 to reflect advances in the... 
Printer Friendly Version
05/01/17LabCorp’s Acquisition of Pathology Associates Medical Laboratories Clears Antitrust Review
BURLINGTON, N.C.--(BUSINESS WIRE)--May 1, 2017-- LabCorp® (NYSE: LH) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to LabCorp’s acquisition of Pathology Associates Medical Laboratories, LLC (PAML) has expired. As previously announced, LabCorp, Providence Health & Services (Providence) and Catholic Health Initiatives (CHI) entered into a definitive agreement for LabCorp t... 
Printer Friendly Version
05/01/17LabCorp Completes Acquisition of Assets of Mount Sinai Health System Clinical Outreach Laboratories
Transaction will benefit physicians and patients in metropolitan New York City BURLINGTON, N.C.--(BUSINESS WIRE)--May 1, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, has completed the previously announced acquisition of assets of the Mount Sinai Health System Clinical Outreach Laboratories. LabCorp is now available to provide comprehensive laboratory services to physicians and patients that previously used Mount Sinai’s ... 
Printer Friendly Version
04/28/17LabCorp to Exclusively Offer the M3 Checklist, a Multi-Condition Mental Health Screening Tool
The M3 Checklist Helps to Identify and Monitor Common Mental Health Conditions in the Primary Care Setting BURLINGTON, N.C. & ROCKVILLE, Md.--(BUSINESS WIRE)--Apr. 28, 2017-- LabCorp® (NYSE:LH) and M-3 Information, LLC today announced the nationwide availability through LabCorp of the peer-reviewed, clinically validated M3 Checklist assessment for mental illness. The M3 Checklist was developed by M3 Information with a goal to reengineer the ... 
Printer Friendly Version
04/25/17Laboratory Corporation of America® Holdings Announces 2017 First Quarter Results and Updates 2017 Guidance
Q1 Net revenue of $2.4 billion, up 5% over last year Q1 Diluted EPS of $1.84, up 16% over last year; Q1 Adjusted EPS of $2.22, up 8% over last year Q1 Free Cash Flow of $162 million, up 188% over last year 2017 Adjusted EPS guidance updated to $9.20 to $9.60, up 4% to 9% over 2016 BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 25, 2017-- Laboratory Corporation of America® Holdings (Lab... 
Printer Friendly Version
04/21/17Covance to Expand Large-Molecule Development Capabilities in the UK
Covance Drug Development continues to invest in precision medicine with expansion into laboratory space at York facility BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 21, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business will expand its biopharmaceutical chemistry, manufacturing and control (BioPharmCMC) capabilities based in... 
Printer Friendly Version
04/03/17Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 3, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
03/30/17LabCorp Commends Reps. Dr. Bucshon, DeGette for Releasing Bipartisan Discussion Draft of the Diagnostic Accuracy and Innovation Act (DAIA)
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 30, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), a leading global life sciences company, today issued the following statement regarding a discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA) recently released by Reps. Dr. Larry Bucshon, R-Ind., and Diana DeGette, D-Colo. “LabCorp commends Reps. Dr. Bucshon and DeGette for their leadership in releasing this... 
Printer Friendly Version
03/29/17LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Company’s Two Primary Business Segments
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 29, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), a leading global life sciences company, today announced that Gary Huff is being promoted to CEO of LabCorp Diagnostics, one of the company’s two primary business segments, effective immediately. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170329005288/en/ Gary Huff... 
Printer Friendly Version
03/13/17LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 13, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2017 to September 11, 2017, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero Coupon Notes) contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading... 
Printer Friendly Version
03/06/17LabCorp is Scheduled to Present at the 2017 Barclays Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 6, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 2017 Barclays Global Healthcare Conference. LabCorp’s presentation is planned for Wednesday, March 15, 2017 at 11:15 AM (ET). A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for replay. About LabCorp® ... 
Printer Friendly Version
03/01/17LabCorp is Scheduled to Present at the 38th Annual Raymond James Institutional Investors Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 1, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 38th Annual Raymond James Institutional Investors Conference. LabCorp’s presentation is scheduled for Tuesday, March 7, 2017 at 11:00 AM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. ... 
Printer Friendly Version
02/23/17LabCorp to Acquire Pathology Associates Medical Laboratories from Providence Health & Services and Catholic Health Initiatives
BURLINGTON, N.C. & RENTON, Wash. & ENGLEWOOD, Colo.--(BUSINESS WIRE)--Feb. 23, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), Providence Health & Services (Providence) and Catholic Health Initiatives (CHI), today announced that they have entered into a definitive agreement for LabCorp to acquire all of the ownership interest in Pathology Associates Medical Laboratories, LLC, (PAML), one of the nation’s premier medica... 
Printer Friendly Version
02/16/17Laboratory Corporation of America® Holdings Announces Record 2016 Fourth Quarter and Full Year Results and Provides 2017 Guidance
Net Revenue: Q4 of $2.4 billion, up 6% over 2015; Full year of $9.4 billion, up 11% over 2015 Diluted EPS: Q4 of $1.75, up 63% over 2015; Full year of $7.02, up 61% over 2015 Adjusted EPS: Q4 of $2.15, up 9% over 2015; Full year of $8.83, up 12% over 2015 Free Cash Flow: Q4 of $375 million, up 25% over 2015; Full year of $897 million, up 23% over 2015 2017 Adjus... 
Printer Friendly Version
01/10/17LabCorp to Acquire Assets of Mount Sinai Health System Clinical Outreach Laboratories
Transaction will benefit physicians and patients in metropolitan New York City BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 10, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a world leading life sciences company, and the Mount Sinai Health System (Mount Sinai), one of the largest health systems in metropolitan New York City, have entered into a definitive agreement for LabCorp to acquire assets of Mount Sinai’s Clinical ... 
Printer Friendly Version
01/05/17LabCorp is Scheduled to Present at the 35th Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 5, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 35th Annual J.P. Morgan Healthcare Conference. LabCorp’s presentation is scheduled for Tuesday, January 10, 2017 at 1:30 PM (PT). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCor... 
Printer Friendly Version
01/04/17Leading Genetic Testing Companies Join Forces to Launch the Coalition for Access to Prenatal Screening
Coalition aims to make noninvasive prenatal testing easily accessible to all pregnant women WASHINGTON, Jan. 4, 2017 /PRNewswire/ -- Today, five leading genetic testing companies in the U.S. are coming together to launch the Coalition for Access to Prenatal Screening (CAPS). This new organization will work to improve access to state-of-the-art prenatal screening using cell-free DNA (cfDNA)-based noninvasive prenatal testing (NIPT). The coalition is comprised of: Ill... 
Printer Friendly Version
01/03/17Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 3, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version